The immunomodulatory properties of
tucaresol (compound
589C80) were tested on in vitro
antigen- and
mitogen-stimulated proliferation and
cytokine production by peripheral blood mononuclear cells (PBMC) of HIV-infected individuals and healthy controls (HC). Results showed that
tucaresol: (1) increases influenza A virus-, gp 160
peptide-, and HLA
alloantigen-stimulated proliferation as well as
interleukin (IL)-2 and
interferon gamma (IFN gamma) production by PBMC of HIV-infected individuals with higher CD4 counts (>500/microl) but had only a marginal immunomodulatory effect on PBMC of patients with lower CD4 counts (<500/microl); (2) did not modify
IL-10 production; (3) augmented CD25 expression on
mitogen-stimulated T cells of HC but not of HIV-infected individuals; and (4) marginally increased CTL activity. The immunomodulatory properties of
tucaresol were confirmed by PCR analyses; additional data showed that
tucaresol costimulated CD3-dependent triggering of T cells and that this stimulation was independent of CD28 costimulation. The immunomodulatory effects of
tucaresol on T cell functions are characterized by a bell-shaped dose response curve; the action of the compound is optimal in the 100 to 300 microM range. Analyses of
mitogen-stimulated apoptosis demonstrated that the lack of effect of
tucaresol at higher doses is not the result of increased cell death, suggesting a role of functional impairment. These data confirm that
tucaresol can stimulate T helper cell function and enhance the production of type 1
cytokines, thus eliciting cell-mediated immunity, and warrant its potential utility in the
therapy of
HIV infection.